C
Circe Biosciences
Energy · Boston, United States · Founded 2021
Developing a manufacturing platform capable of producing any organic molecule using carbon dioxide, water, and electricity MoreLess
Circe Biosciences, Inc. operates at the intersection of synthetic biology and decarbonization, developing a manufacturing platform that transforms carbon dioxide into a variety of valuable chemicals. The company was co-founded by Shannon Nangle and Marika Ziesack, who both bring extensive experience from the Wyss Institute for Biologically Inspired Engineering at Harvard University. Their collective background in gas fermentation and synthetic biology underpins the company's core technology. The process leverages gas fermentation, utilizing microbes that consume greenhouse gases like carbon dioxide, along with water and electricity, to produce a range of organic molecules.
The primary goal is to provide a sustainable alternative to traditional petrochemical-based manufacturing, thereby reducing the carbon footprint of numerous industries. Circe Biosciences' platform is designed to create products such as triglycerides for food production, bioplastics, and other specialty chemicals. This approach targets industries reliant on these materials, offering them a method to decarbonize their supply chains. The business model appears to be centered on producing and selling these sustainably sourced molecules or potentially licensing the technology to large-scale manufacturing partners. By converting a waste product (CO2) into essential goods, the company aims to build a more resilient and circular economy.
The company's platform functions by engineering microbes to be highly efficient at converting CO2 into specific target molecules. This fermentation process is positioned as a direct competitor to conventional methods that rely on fossil fuels. Significant milestones include securing a $1 million investment from The Engine, a venture firm with roots at MIT, which has provided crucial early-stage support. The company has also been recognized through various awards, including participation in the 2022 cohort of the Third Derivative accelerator program, underscoring its potential impact on climate technology. This technology offers the benefit of producing familiar products through a fundamentally different and more environmentally friendly pathway.
Keywords: gas fermentation, carbon capture, synthetic biology, decarbonization, sustainable manufacturing, alternative proteins, biochemicals, climate tech, circular economy, industrial biotechnology
Company overview
Circe Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 51
- Open positions
- None listed
- Dealroom signal
- 61.6
Valuation & funding
Circe Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Sep 2024 | $5M | $40M | Bee Partners · Ponderosa Ventures · ReGen Ventures · Safar Partners | — |
| EARLY VC✓Equity / VC | May 2024 | $8M | $32M | Bee Partners · Undeterred Capital · ReGen Ventures · Elementum Ventures | ↗ |
| SUPPORT PROGRAM✓Other financing | Oct 2021 | $0 | — | Activate | — |
| SPINOUT✓Other financing | Oct 2021 | $0 | — | Harvard University · Wyss Institute | — |
| GRANT✓Other financing | May 2021 | $3M | — | ARPA-E | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 51 |
| 2025 | 51 |
| 2024 | 39 |
| 2023 | 43 |
| 2022 | 13 |
| 2021 | 3 |
Growth signals
Circe Biosciences website traffic
Latest recorded traffic for Circe Biosciences is 410 monthly website visits, down 48.1% over the last three months. Circe Biosciences's team grew 0% over the past year.
Comparisons
Circe Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Circe Biosciences's talent
Source: Dealroom Talent Intelligence.
Investors
13 investors on Circe Biosciences's cap table
Sourced from Dealroom's funding and investor records.













Global footprint
Where Circe Biosciences has talent and traffic
team presence
In the news
Latest news about Circe Biosciences
Recent press, funding announcements, and product moves mentioning Circe Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Circe Biosciences
An AI-synthesized read of the highest-engagement posts about Circe Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Circe Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







